Live Coronavirus Updates

The Trump administration chose 5 companies as the most likely to produce a vaccine. The tally of new cases is rising in the U.S., partly because of expanded testing. Italy ends travel restrictions.
Source: NYT Health - Category: Consumer Health News Tags: Coronavirus (2019-nCoV) Source Type: news

Related Links:

Some experts say a vaccine puffed in the nose would be better at protecting people from infection. But nasal vaccines won ’t be ready right away.
Source: NYT Health - Category: Consumer Health News Authors: Tags: your-feed-science Coronavirus (2019-nCoV) Vaccination and Immunization Immune System Source Type: news
Here is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
Canadian trials have just begun for a prospective coronavirus vaccine, but its Quebec-based manufacturer is already downplaying its potential impact, cautioning observers against holding unrealistic expectations that his product — or any of the numerous vaccines in development globally — will bring the pandemic to a screeching halt.
Source: CBC | Health - Category: Consumer Health News Tags: News/Health Source Type: news
Work on a vaccine to halt the HIV epidemic has failed so far. But it has resulted in expertise, technology and infrastructure that is quickly pivoting toward the coronavirus.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news
This article examines the role denial plays in medicine’s never-ending quest for cures.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation Coronavirus business pharma Source Type: news
While the immune response to SARS-CoV-2 is not yet well understood, insights may be gained from studies of other coronavirus infections. Here, Sariol and Perlman review the literature on animal and human coronavirus infections and discuss the critical outstanding questions for understanding SARS-CoV-2 vaccination and protective immunity.
Source: Immunity - Category: Allergy & Immunology Authors: Tags: Review Source Type: research
Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
r Erica Bickerton The Gammacoronavirus infectious bronchitis virus (IBV) is a highly contagious economically important respiratory pathogen of domestic fowl. Reverse genetics allows for the molecular study of pathogenic determinants to enable rational vaccine design. The recombinant IBV (rIBV) Beau-R, a molecular clone of the apathogenic Beaudette strain, has previously been investigated as a vaccine platform. To determine tissues in which Beau-R could effectively deliver antigenic genes, an in vivo study in chickens, the natural host, was used to compare the pattern of viral dissemination of Beau-R to the pathogenic...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
ET has gathered that China is taking advantage of Covid to exploit developing and least developed countries across sectors from pharma to trade. Last month there were reports that China may run the second phase trial of the coronavirus vaccine in Bangladesh.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
As Foster City-based Gilead Sciences moves forward with remdesivir and other Bay Area companies pursue new or repurposed drugs and vaccines against Covid-19 and the coronavirus that causes the disease, NIAID chief Dr. Tony Fauci talked in a webinar with Dr. Lloyd Minor, Stanford University's medical school dean.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
More News: American Health | Coronavirus | COVID-19 | Health | Italy Health | Trump | USA Health | Vaccines